Lantheus Exits Perspective Therapeutics Stake, Selling 4M Shares
LNTH sits 97% above its 52-week low of $51.47.
Summary
Lantheus Alpha sold 4,000,000 Perspective Therapeutics shares across October 5 and November 10, 2026, dropping its stake to 3.9% and ending its position as a greater-than-5% holder. The November 10 tranche of 3,000,000 shares averaged $0.80, well below the $101.25 price shown for today.
Key Events · Ownership and Investor Activity · LNTH
-
Lantheus Sells 4M Shares
Lantheus Alpha sold 1,000,000 shares on October 5, 2026 at an average $2.75 and 3,000,000 shares on November 10, 2026 at an average $0.80.
-
Stake Falls to 3.9%
The reporting persons now hold 4,739,011 shares, or 3.9% of the 120,758,815 shares outstanding as of November 4, 2026.
-
Exit Filing Ends 13D
The reporting persons ceased to be beneficial owners of more than five percent on November 10, 2026; Amendment No. 4 is the final amendment and an exit filing.
-
Sale Price Drops Sharply
The average sale price fell from $2.75 on October 5 to $0.80 on November 10, while the stock price shown for today is $101.25; the filing states share counts are adjusted for the June 14, 2024 1-for-10 reverse split.
Analysis · LNTH · Life Sciences
Lantheus Alpha sold 1,000,000 shares on October 5, 2026 at an average $2.75 and another 3,000,000 shares on November 10, 2026 at an average $0.80, cutting its stake to 4,739,011 shares, or 3.9% of the 120,758,815 shares outstanding as of November 4, 2026. The November 10 sale cleared the 5% threshold, so this Amendment No. 4 is the final filing and an exit. The average price on the larger sale, $0.80, is far below the $101.25 stock price shown for today, a gap that suggests the filing's per-share figures and the market data are not on the same basis; the filing notes the numbers are adjusted for the June 14, 2024 1-for-10 reverse split. A strategic holder liquidating its remaining position removes a large overhang but also removes an anchor investor, and the steep drop in the average sale price between October and November points to weak demand for the shares.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNTH was trading at $101.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $51.47 to $111.86. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.